1 / 16

Anal Squamous Cell Carcinoma: Single Centre Observational Study Over 6 Years

Anal Squamous Cell Carcinoma: Single Centre Observational Study Over 6 Years. Steve Emmett Edmund Leung Natalie Acors James Francombe. Introduction I. Anal carcinoma (SCC) has an incidence of ~2/100,000 Peak incidence in 70 th decade, but highly variable Known associations include:

ulema
Télécharger la présentation

Anal Squamous Cell Carcinoma: Single Centre Observational Study Over 6 Years

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Anal Squamous Cell Carcinoma: Single Centre Observational Study Over 6 Years Steve Emmett Edmund Leung Natalie Acors James Francombe

  2. Introduction I • Anal carcinoma (SCC) has an incidence of ~2/100,000 • Peak incidence in 70th decade, but highly variable • Known associations include: • Human papilloma virus (HPV-16, 18 & 31) • Female gender (many series of data) • HIV positive • Sexual promiscuity- particularly receptive anal intercourse • Cigarette smoking • In HIV-positive patients rates ~37/100,000

  3. Introduction II • Anal Cancers only represent 1-2% of GI malignacies: • Squamous cell carcinoma commonest • Adenocarcinoma of anal glands rarer • Melanoma rarer still • Presents primarily with • Proctalgia and/or • PR bleed • Spread is primarily lymphatic • Distal anal canal drains to inguinal nodes, femoral and hence ext iliac • Proximal tumours drain to mesorectal, then inf mesenteric, to paraaortic.

  4. Methods I • Single centre study- pilot study • Retrospective analysis over last 6 years • Inclusion criteria • Histologically diagnosed ASCC • Both anal canal and anal margin were included

  5. Methods II • Variables • TNM-stage • Age • Sex • Location • Risk factors • Cigarette Smoker • Alcohol >21 units/wk (male), >14 units/wk (female) • HPV status • Immunocomprised • Treatment modality • Recurrent rates

  6. Methods II • Follow up • Recurrence and mortality was point analysed within a median 20 month period (6-60 months) • Also recurrence and mortality was manually stratified in to 1 yr and 3 yr post diagnosis follow up. • Analysis • All data were analysed using product moment co-efficient and chi2 test. Significance p<0.05 • Survival data was analysed by Mantel-Cox test.

  7. Results I: Incidence • 23 patients were identified over 6 years • Age range 29-81 • Median 60 • 13 males, 10 females • Our incidence was 1.5/100,000 • The incidence of ASCC remained static over the last 6 years (r=0.43) • Period prevalence is 2.1/100,000

  8. Results II: Clinical presentation • The commonest presentations were: • Perianal bleeding (56%) • Proctalgia (30%). • No association between period prevalence and heavy smoking or excess alcohol consumption (p>0.05). • Formal HPV testing performed on only 22%

  9. Key to map Key to map New cases by year 2001 (n=1) 2002 (n=2) 2003 (n=5) 2004 (n=1 (+1 missing)) 2005 (n=1) 2006 (n=3) 2007 (n=8 (+1 missing)) New cases by year 2001 (n=1) 2002 (n=2) 2003 (n=5) 2004 (n=1 (+1 missing)) 2005 (n=1) 2006 (n=3) 2007 (n=8 (+1 missing)) Results III: Demographics • ASCC in South Warwickshire Highest density cluster • Cases not associated with population density • Highest prevalence; 4 cases within 1 mile radius over 5 years

  10. Results IV: Staging & Treatment • Staging breakdown • 13% were Tx • 9% were T1 • 43% were T2 • 22% were T3 • 9% were T4 • 35% underwent surgical treatment • 17% (total n=4) had primary excision with no further intervention • The remaining 18% had surgery ± chemotherapy or radiotherapy • 61% underwent chemoradiotherapy • 17% required salvage surgery • 4% had not yet undergone treatment at time of analysis

  11. Results V: Recurrence • Median follow up was 20 months (range 6-60 mo) post diagnosis • Overall recurrence and mortality rates were associated with advanced (T3 or T4) tumours at diagnosis (p<0.05). • Overall recurrence was 22% • 2 pts has local recurrence • 3 pts had a distal site of recurrence (mainly original high grade tumours) • Surgical recurrence rate of 13% • Chemoradiotherapy recurrence rate of 9%

  12. Results VI: Mortality • Overall period mortality was 17% • Of pts after 1 complete year follow up • 4% had recurrence • With no mortality • Of pts followed up after >3 years • 17% had recurrence • Mortality was 13% (n=3) • There was no significant difference between surgical and chemorad treatments • Median survival in chemorad group was 84 months

  13. Discussion I: Incidence/Prevalence/Mortality • Our period prevalence of ASCC appears slightly lower than many centers previously reported. • Despite our belief that prevalence was locally on the increase it remained static. • Previous reports show 5 yr survival at 58-90% • Our overall 3 yr survival was 87%, similar to other 3yr follow up studies (Arnott et al., 1996; Sischy et al,. 1989) • Our median survival was 84months • Due to our small number of patients there was no differences in mortality from surgical or chemo radiotherapy. • Numerous studies (ACTI, EORTC, RTOG) have established chemo-radiotherapy is the treatment of choice

  14. Discussion II: Recurrence • Recurrence rates have reportedly been 7-30% • Our current data showed similar recurrence rates (22%) • Our surgical recurrence rate of 13% was mainly made up of low grade tumours • While the chemo-radiation group recurrence rate was 9%; made up of generally higher grades • In our study most low grade tumours were managed with local excision • Although a small n our surgical outcomes appear worse: • Even small, discrete tumours may benefit from chemoradiotherapy • Reflects the importance of follow up

  15. Discussion III • In 2007 the British Association of Coloproctology published clear guidelines on anal cancer management: • Ensure Hx asks smoking habits • At presentation consider HIV, HPV testing • Accurate assessment of size of tumour • All pts should be discussed at MDT • Given the clear associations of HPV with ASCC our data showed poor clinical screening for the virus within our centre • All pts in our centre now undergo HIV and HPV screening on diagnosis • On diagnosis pts also undergo HPV vaccination • The UKDoH/NHS has now introduced non-compulsory HPV vaccinations for girls aged 12-13 (plus catch-up group) • A potential new & different cohort • Further study should be considered on populations to establish the impact on prevalence of anal SCC.

  16. Conclusion • Our incidence, recurrence and survival are consistent with current literature • Study has resulted in changes to local screening and follow-up procedures • Even low grade tumours may benefit from chemoradiotherapy Acknowledgments • University Hospital Coventry and Warwickshire • Mr J. Francombe and Mr Murphy, Warwick hospital • Mr V. Menon, Upper GI Surgeon, UHCW

More Related